拯救脓毒症运动:成人COVID-19重症监护管理指南(首次更新)
拯救脓毒症运动COVID-19专家组扩展至14个国家43名专家,采用WHO重型/危重型COVID-19定义,围绕ICU管理9个问题更新指南。采用GRADE方法评估证据质量,通过证据到决策框架生成推荐。共发布9条声明(3条新订、6条更新):强烈推荐全身糖皮质激素和静脉血栓预防,强烈反对羟氯喹;建议使用地塞米松(相较于其他糖皮质激素),建议不(弱推荐)使用恢复期血浆和治疗性抗凝(临床试验外);建议瑞德西韦用于未插管的重型COVID-19患者,建议不(弱推荐)在临床试验外对危重型COVID-19患者启动瑞德西韦;因证据不足未对清醒俯卧位作出推荐。
要点
- 重症或危重型COVID-19 ICU患者:强烈推荐使用全身糖皮质激素。
- 重症或危重型COVID-19 ICU患者:强烈推荐进行静脉血栓预防。
- 重症或危重型COVID-19 ICU患者:强烈反对使用羟氯喹。
- 建议使用地塞米松(相较于其他糖皮质激素)(弱推荐);建议不(弱推荐)在临床试验外使用恢复期血浆和治疗性抗凝。
- 建议瑞德西韦用于未插管的重型COVID-19患者(弱推荐);建议不(弱推荐)在临床试验外对危重型COVID-19患者启动瑞德西韦;因证据不足未对清醒俯卧位作出推荐。
适用人群与场景
- ICU内重型或危重型COVID-19成人患者,采用世界卫生组织(WHO)重型/危重型COVID-19定义。
诊断标准与关键阈值
- 采用世界卫生组织(WHO)重型/危重型COVID-19定义界定目标人群。
处置流程与药物剂量
- 重症或危重型COVID-19:强烈推荐使用全身糖皮质激素。
- 重症或危重型COVID-19:强烈推荐进行静脉血栓预防。
- 重症或危重型COVID-19:强烈反对使用羟氯喹。
- 建议使用地塞米松(相较于其他糖皮质激素)(弱推荐)。
- 建议不(弱推荐)在临床试验外使用恢复期血浆。
- 建议不(弱推荐)在临床试验外使用治疗性抗凝。
- 建议瑞德西韦用于未插管的重型COVID-19患者(弱推荐)。
- 建议不(弱推荐)在临床试验外对危重型COVID-19患者启动瑞德西韦。
研究设计与关键结果
- 拯救脓毒症运动COVID-19专家组扩展至43名专家,来自14个国家,所有成员完成电子利益冲突披露表。
- 本次更新针对ICU内重型或危重型COVID-19管理相关的9个问题。
- 系统评价团队检索文献以识别系统评价和临床试验,适当时采用随机效应荟萃分析汇总治疗效果。
- 采用GRADE方法评估证据质量,并使用证据到决策框架生成推荐,考虑获益与危害平衡、资源与成本、公平性和可行性。
- 共发布9条声明(3条新订、6条更新)。
证据类型、等级与局限
- 证据类型:指南(拯救脓毒症运动COVID-19指南首次更新),采用GRADE方法评估证据质量,通过证据到决策框架生成推荐。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对ICU内重症或危重型COVID-19成人患者,应使用全身糖皮质激素(强烈推荐)。
- 对ICU内重症或危重型COVID-19成人患者,应进行静脉血栓预防(强烈推荐)。
- 对ICU内重症或危重型COVID-19成人患者,不应使用羟氯喹(强烈推荐反对)。
- 地塞米松可考虑用于重症或危重型COVID-19(相较于其他糖皮质激素)(弱推荐)。
- 恢复期血浆和治疗性抗凝不建议在临床试验外使用(弱推荐反对)。
- 瑞德西韦建议用于未插管的重型COVID-19患者(弱推荐),不建议在临床试验外对危重型COVID-19患者启动瑞德西韦(弱推荐反对)。
- 清醒俯卧位因证据不足未作出推荐。
指南或共识出处
- 拯救脓毒症运动COVID-19指南:成人COVID-19重症监护管理(首次更新),发表于Critical Care Medicine。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The coronavirus disease 2019 pandemic continues to affect millions worldwide. Given the rapidly growing evidence base, we implemented a living guideline model to provide guidance on the management of patients with severe or critical coronavirus disease 2019 in the ICU.
METHODS: The Surviving Sepsis Campaign Coronavirus Disease 2019 panel has expanded to include 43 experts from 14 countries; all panel members completed an electronic conflict-of-interest disclosure form. In this update, the panel addressed nine questions relevant to managing severe or critical coronavirus disease 2019 in the ICU. We used the World Health Organization's definition of severe and critical coronavirus disease 2019. The systematic reviews team searched the literature for relevant evidence, aiming to identify systematic reviews and clinical trials. When appropriate, we performed a random-effects meta-analysis to summarize treatment effects. We assessed the quality of the evidence using the Grading of Recommendations, Assessment, Development, and Evaluation approach, then used the evidence-to-decision framework to generate recommendations based on the balance between benefit and harm, resource and cost implications, equity, and feasibility.
RESULTS: The Surviving Sepsis Campaign Coronavirus Diease 2019 panel issued nine statements (three new and six updated) related to ICU patients with severe or critical coronavirus disease 2019. For severe or critical coronavirus disease 2019, the panel strongly recommends using systemic corticosteroids and venous thromboprophylaxis but strongly recommends against using hydroxychloroquine. In addition, the panel suggests using dexamethasone (compared with other corticosteroids) and suggests against using convalescent plasma and therapeutic anticoagulation outside clinical trials. The Surviving Sepsis Campaign Coronavirus Diease 2019 panel suggests using remdesivir in nonventilated patients with severe coronavirus disease 2019 and suggests against starting remdesivir in patients with critical coronavirus disease 2019 outside clinical trials. Because of insufficient evidence, the panel did not issue a recommendation on the use of awake prone positioning.
CONCLUSION: The Surviving Sepsis Campaign Coronavirus Diease 2019 panel issued several recommendations to guide healthcare professionals caring for adults with critical or severe coronavirus disease 2019 in the ICU. Based on a living guideline model the recommendations will be updated as new evidence becomes available.
参考来源
- Alhazzani W, Evans L, Alshamsi F, et al. Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First Update. Crit Care Med. 2021. PMID: 33555780. doi:10.1097/CCM.0000000000004899
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。